Quantcast

Latest Management of cancer Stories

2014-10-07 12:31:24

LA JOLLA, Calif., Oct. 7, 2014 /PRNewswire/ -- Avidity NanoMedicines today announced that it has expanded its investor syndicate through the closing of a $6 million convertible note financing co-led by Fidelity Biosciences and TPG Biotech. Other investors in the financing include Brace Pharmaceuticals, Partner Fund Management, L.P. and existing investor Alethea Capital Management. Ben Auspitz from Fidelity Biosciences and Eran Nadav, Ph.D. from TPG Biotech will join Avidity's board as...

2014-10-07 08:28:48

University of Mannheim Medical Center is first site opened TORONTO and CHICAGO, Oct. 7, 2014 /PRNewswire/ - Pinnacle Biologics, Inc. ("Pinnacle"), a subsidiary of Concordia Healthcare Corp., ("Concordia") (TSX: CXR) (OTCQX: CHEHF), announced today the initiation of the pivotal Phase 3 trial (OPUS) in Germany for a rare form of bile duct cancer for which there is currently no acceptable therapy. OPUS is an Open-label, multicenter phase 3 on the efficacy and safety of Photodynamic...

2014-10-02 12:28:31

LONDON, Oct. 2, 2014 /PRNewswire/ -- This report focuses on the rising potential for the newest and most promising of cancer treatments: cancer immunotherapy. Cancer immunotherapy was once just a dream in the minds of physicians, clinicians and patients, but only recently (2010s era) has it actually been within reasonable reach. Cancer Immunotherapy: immune checkpoint inhibitors, cancer vaccines, and adoptive T-cell therapies covers three principle therapies that have been in the...

2014-10-02 08:24:49

LUGANO, Switzerland, October 2, 2014 /PRNewswire/ -- Rare cancer patients need access to innovative cancer drugs A consensus paper published in the Annals of Oncology today by Rare Cancers Europe (RCE) calls for new methodologies to be applied to clinical studies in rare cancers. RCE - a multi-stakeholder initiative representing patient associations, medical societies and industry - is calling both the community of researchers and European authorities to address...

2014-09-29 16:23:53

In the news release, The Gastric Cancer Market is Expected to More Than Triple Over the Next Ten Years, Capturing Nearly $3.8 million by 2023, issued 18-Sep-2014 by Decision Resources Group over PR Newswire, we are advised by the company that the headline should read $3.8 billion rather than $3.8 million as originally issued inadvertently. The complete, corrected release follows: The Gastric Cancer Market is Expected to More Than Triple Over the Next Ten Years, Capturing Nearly $3.8 billion...

2014-09-29 12:30:45

BOGOTA, Colombia, Sept. 29, 2014 /PRNewswire/ -- Cancer Treatment Institute of Colombia has announced a promising new drug treatment: a carefully formulated, first-of-its-kind combination of salinomycin and 3-bromopyruvate (3-BrPA) that has already proven successful at treating multiple types of cancer. The team of medical researchers behind this novel treatment are optimistic that it could significantly improve outcomes for many patients who have exhausted current therapeutic...

pregnancy and cancer
2014-09-29 02:30:13

European Society for Medical Oncology Presentations at ESMO 2014 examine the impact of in-utero exposure to chemotherapy and radiotherapy, the safety of lymph node biopsy in pregnancy, and the outcomes of unplanned pregnancy during cancer treatment Children who are exposed to chemotherapy or radiotherapy while in the womb suffer no negative impacts on mental or cardiac development, international studies presented at the ESMO 2014 Congress in Madrid have shown. "When chemotherapy is...

Study Finds Many Patients Excluded From Clinical Trials Due To Prior Cancer
2014-09-29 03:46:37

UT Southwestern Medical Center Lung cancer clinical trials exclude a substantial proportion of patients due to a history of prior cancer, as shown in an analysis by cancer researchers at UT Southwestern Medical Center. Among more than 50 lung cancer clinical trials examined, more than 80 percent excluded patients with prior cancer from participating, according to the study published in the Journal of the National Cancer Institute. The exclusion criterion was even applied in more than...

newseventsimages
2014-09-28 08:42:24

Chuck Bednar for redOrbit.com – Your Universe Online Researchers at Imperial College London have identified a molecule that blocks the activity of a disease-causing enzyme – a breakthrough that could ultimately lead to the development of a wonder drug that could be used to fight cancer, neurodegenerative conditions such as Alzheimer’s disease, and even diabetes. Writing in Friday’s edition of Nature Communications, lead investigator Ed Tate, a professor in the school’s...

2014-09-26 23:00:20

Treatment designed to reduce pain and inflammation associated with radiation therapy to the lower bowel. Claremont, CA (PRWEB) September 27, 2014 Synedgen announced today the award of a competitive Small Business Innovation Research (SBIR) Phase I contract from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) to demonstrate proof-of-concept activity of Synedgen’s proprietary treatment for radiation proctitis, a condition that causes painful tissue damage to...


Word of the Day
negawatt
  • A unit of saved energy.
Coined by Amory Lovins, chairman of the Rocky Mountain Institute as a contraction of negative watt on the model of similar compounds like megawatt.